Asia-Pacific Gastrointestinal Drugs Market Research Report Forecast to 2023

Report / Search Code: MRFR/Pharma/0190-CRR  Publish Date: 15 October, 2017

Request Sample

| Price   | 1-user PDF : $3500.0 | Enterprise PDF : $5300.0 |

Description:

Gastrointestinal Drugs Market Information: By Drug Class (Acid Neutralizers, Laxatives & Antidiarrheal, Anti-Emetics, Antiulcer), By Type Of Disease (Esophagus Diseases, Stomach Diseases, Intestinal Diseases, Rectum Diseases) – Asia Forecast till 2023

Intended Audience

- Pharmaceutical Companies
- Medical Devices Companies
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors

Market Scenario

Gastrointestinal (GI) diseases affects stomach, large intestine and rectum, small intestine, esophagus, liver, gallbladder, and pancreas. The symptoms of GI diseases are heartburn, indigestion, bloating, constipation, and many more. The diseases of gastrointestinal have become common in the people across world. Gastrointestinal diseases are caused by various reasons such as acid reflux, heartburn, indigestion, nausea and vomiting, peptic ulcer disease, abdominal pain syndrome, biliary tract disorders, gallbladder disorders, and gallstone pancreatitis.

Gastrointestinal diseases has gained a tremendous attention over the last few years. Owing to increasing prevalence of different gastrointestinal diseases and disorders, encouraged many companies for initiating the research in the development of innovative and advanced drugs. Furthermore, increasing prevalence of GI diseases, rising geriatric population, and increasing investment in research & development drives the growth of the market. Additionally, changing lifestyle and increasing awareness about the availability of the treatment fuel the market growth.

From the few last decades, the government of Asian countries have been educating the people about the various diseases and their treatment availability. Relief International, with funding from the European Union, is working with Bangladesh citizens to implement One Health Asia, a program designed to prevent zoonotic diseases through training and education. Many organizations and companies are conducting surveys and programs to educate the peoples about the diseases and treatment.

Ageing, decreases the immunity of the body and increases the probability of diseases. According to Economic and Social Commission for Asia and the Pacific (ESCAP), in 2016, approximately 12.4% of the population in the region was over 60 years. According to Asian Development Bank, it was estimated that by 2050, 15% of total Malaysian population will be over 65 year old and in China, the elderly population will reach over 300 million by 2050. Thus, the increasing geriatric population in Asia likely to help the growth of the market over the forecast period.
On the other hand, the presence of misbranded & spurious drugs, and unavailability of lifelong cure may hinder the market growth over the review period.

The Asia gastrointestinal drugs market is expected to grow at a CAGR of 6.1% during the forecast period 2017-2023.

**Research Methodology**

Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, market research future analysis, annual report, white paper, company presentation

**Segmentation**

The Asia gastrointestinal drugs market is segmented on the basis of drug class and type of disease.

On the basis of drug class, it is segmented into acid neutralizers, laxatives & antidiarrheal, antiemetics, antiulcer, and others.

On the basis of type of disease, it is segmented into esophagus diseases, stomach diseases, intestinal diseases, rectum diseases, and others.

**Figure: Asia Gastrointestinal Drugs Market, by Region, 2016 (%)**

Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, market research future analysis, annual report, white paper, company presentation

**Key Findings**
The Asia gastrointestinal drugs market is expected to reach USD 20,772.4 million by 2023 at a CAGR of 6.1%

Acid neutralizers segment accounted for the largest market share with 33.3% of the Asia gastrointestinal drug market, by drug types in 2016.

In 2016, Esophagus diseases segment accounted for the major share of the market as it was the most widely occurring GI disease. The Asia esophagus diseases market by type of diseases is expected to reach USD 7,427.6 million by 2023, growing at a CAGR of 6.32% from 2017 to 2023.

India is expected to be the fastest growing market at a CAGR of 6.60% during the forecast period.

Regional Analysis

Asia gastrointestinal drugs market is segmented on the basis of region: China, India, Republic of Korea, and Rest of Asia. Japan accounts for the major share of the market owning to the well-developed technology and high healthcare expenditure. People in this region are more focused on health, which drive the growth of the market. China is the second largest market, which is followed by India. Owing to the government support for the research & development, well-developed healthcare infrastructure, and high health care expenditure drive the China gastrointestinal drugs market. India is the fastest growing gastrointestinal drugs market across the region. Increasing need for the better treatment methods rapidly changing the healthcare sector. Additionally, the presence of huge opportunities for the development of the market have boosted the market growth.

Developing nations, for instance, India is experiencing high demand for gastrointestinal disorder drugs. Major pharmaceuticals drug manufacturers are using their technology and services to develop new drugs for gastrointestinal diseases to meet the growing demand.

Key Players

Some of the key players in this market are Abbott, Allergan Plc, AstraZeneca, Eli Lilly Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Pfizer Inc, Valeant Pharmaceuticals, and others.
4.4 Opportunities 24
4.4.1 Development of new drugs 24
5 Market Factor Analysis
5.1 Porters Five forces Model 25
5.1.1 Bargaining Power Of Suppliers 26
5.1.2 Bargaining Power Of Buyers 26
5.1.3 Threat Of New Entrants 26
5.1.4 Threat Of Substitutes 26
5.1.5 Intensity Of Rivalry 26
5.2 Value Chain Analysis 27
5.2.1 R&D 27
5.2.2 Manufacturing 27
5.2.3 Distribution & Sales 28
5.2.4 Post-Sales Monitoring 28
5.3 Demand & Supply: Gap Analysis 28
5.4 Pricing Analysis 29
5.5 Investment Opportunity Analysis 29
5.6 Market Access Analysis 29
6 Asia Gastrointestinal Drugs Market, By Drug Class
6.1 Introduction 30
6.2 Acid Neutralizers 32
6.3 Laxatives and Antidiarrheal 33
6.4 Antiemetics 34
6.5 Antiulcer 34
7 Asia Gastrointestinal Drugs Market, By Type of Diseases
7.1 Introduction 35
7.2 Esophagus diseases 37
7.3 Stomach diseases 38
7.4 Intestinal diseases 38
7.5 Rectum Diseases 39
8 Asia Gastrointestinal Drugs Market, By Region
8.1 Introduction 40
8.2 Japan 42
8.3 China 44
8.4 India 46
8.5 Korea 48
8.6 Rest of Asia 51
8.6.1 Malaysia 54
8.6.2 Singapore 56
8.6.3 Indonesia 59
8.6.4 Thailand 61
8.6.5 Philippines 64
8.6.6 Vietnam 66
8.6.7 Others 68
9 Company Profile
9.1 Abbott 71
9.1.1 Company Overview 71
9.1.2 Product/Business Segment Overview 71
9.1.3 Financial Overview 72
9.1.4 Key Development 74
9.1.5 SWOT Analysis 75
9.2 Allergan Plc 76
9.2.1 Company Overview 76
9.2.2 Product/Business Segment Overview 76
9.2.3 Financial Overview 77
9.2.4 Key Developments 78
9.2.5 SWOT Analysis 78
9.3 AstraZeneca 79
9.3.1 Company Overview 79
9.3.2 Product/Business Segment Overview 79
9.3.3 Financial Overview 80
9.3.4 Key Development 81
9.3.5 SWOT Analysis 82
9.4 Eli Lilly Company 83
9.4.1 Company Overview 83
9.4.2 Product/Business Segment Overview 83
9.4.3 Financial Overview 83
9.4.4 Key Development 84
9.4.5 SWOT Analysis 85
9.5 F. Hoffmann-La Roche Ltd 86
9.5.1 Overview 86
9.5.2 Product/Business Segment Overview 86
9.5.3 Financial Overview 86
9.5.4 Key Development 87
9.5.5 SWOT Analysis 88
9.6 GlaxoSmithKline plc. 89
9.6.1 Company Overview 89
9.6.2 Product/ Business segment overview 89
9.6.3 Financial Overview 89
9.6.4 Key Development 91
9.6.5 SWOT Analysis 92
9.7 Pfizer Inc 93
9.7.1 Overview 93
9.7.2 Product/Business Segment Overview 93
9.7.3 Financial Overview 93
9.7.4 Key Development 94
9.7.5 SWOT Analysis 95
9.8 Valeant Pharmaceuticals 96
9.8.1 Company Overview 96
9.8.2 Product overview 96
9.8.3 Financial Overview 97
9.8.4 Key Development 98
9.8.5 SWOT Analysis 99
10 Company Landscape
10.1 Introduction 100
10.2 Company Share Analysis 100
10.3 Key Developments 101
11 Conclusion
11.1 Key Findings 103
11.1.1 CEO's Viewpoint 103
11.1.2 Unmet Needs 103
11.1.3 Key Companies to Watch 103
11.1.4 Prediction of Asia Gastrointestinal Drugs Industry 103
12 Appendix
12.1 Discussion Blue Print 104
12.2 References 105
13 List of Tables
TABLE 1 PRIMARY INTERVIEWS 19
TABLE 2 ASIA GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS, 2014-2023 (USD MILLION) 31
TABLE 3 ACID NEUTRALIZERS GASTROINTESTINAL DRUGS MARKET, BY REGION, 2014-2023 (USD MILLION) 32
TABLE 4 LAXATIVE AND ANTIARRHEAL GASTROINTESTINAL DRUGS MARKET, BY REGION, 2014-2023 (USD MILLION) 33
TABLE 5 ANTIEMETIC GASTROINTESTINAL DRUGS MARKET, BY REGION, 2014-2023 (USD MILLION) 34
TABLE 6 ANTIULCER GASTROINTESTINAL DRUGS MARKET, BY REGION, 2014-2023 (USD MILLION) 34
TABLE 7 ASIA GASTROINTESTINAL DRUGS MARKET, BY TYPE OF DISEASES, 2014-2023 (USD MILLION) 36
TABLE 8 ESOPHAGUS DISEASES GASTROINTESTINAL DRUGS MARKET, BY REGION, 2014-2023 (USD MILLION) 37
TABLE 9 STOMACH DISEASES GASTROINTESTINAL DRUGS MARKET, BY REGION, 2014-2023 (USD MILLION) 38
TABLE 10 INTESTINAL DISEASES GASTROINTESTINAL DRUGS MARKET, BY REGION, 2014-2023 (USD MILLION) 38
TABLE 11 RECTUM DISEASES GASTROINTESTINAL DRUGS MARKET, BY REGION, 2014-2023 (USD MILLION) 39
TABLE 12 ASIA GASTROINTESTINAL DRUGS MARKET, BY REGION, 2014-2023 (USD MILLION) 41
TABLE 13 JAPAN GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS, 2014-2023 (USD MILLION) 42
TABLE 14 JAPAN GASTROINTESTINAL DRUGS MARKET, BY TYPE OF DISEASES, 2014-2023 (USD MILLION) 43
TABLE 15 CHINA GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS, 2014-2023 (USD MILLION) 44
TABLE 16 CHINA GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2014-2023 (USD MILLION) 45
TABLE 17 INDIA GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS, 2014-2023 (USD MILLION) 46
TABLE 18 INDIA GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2014-2023 (USD MILLION) 47
TABLE 19 KOREA GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS, 2014-2023 (USD MILLION) 48
TABLE 20 KOREA GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2014-2023 (USD MILLION) 50
TABLE 21 REST OF ASIA GASTROINTESTINAL DRUGS MARKET, BY REGION, 2014-2023 (USD MILLION) 51
TABLE 22 REST OF ASIA GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS, 2014-2023 (USD MILLION) 52
TABLE 23 REST OF ASIA GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2014-2023 (USD MILLION) 53
TABLE 24 MALAYSIA GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS, 2014-2023 (USD MILLION) 54
TABLE 25 MALAYSIA GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2014-2023 (USD MILLION) 55
TABLE 26 SINGAPORE GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS, 2014-2023 (USD MILLION) 56
TABLE 27 SINGAPORE GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2014-2023 (USD MILLION) 57
TABLE 28 INDONESIA GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS, 2014-2023 (USD MILLION) 59
TABLE 29 INDONESIA GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2014-2023 (USD MILLION) 60
TABLE 30 THAILAND GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS, 2014-2023 (USD MILLION) 61
TABLE 31 THAILAND GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2014-2023 (USD MILLION) 62
TABLE 32 PHILIPPINES GASTROINTESTINAL DRUGS MARKET, BY DRUG CLASS, 2014-2023 (USD MILLION) 64
TABLE 33 PHILIPPINES GASTROINTESTINAL DRUGS MARKET, BY TYPES OF DISEASES, 2014-2023 (USD MILLION) 65